A comparison of preferences for two GLP-1 products – liraglutide and exenatide – for the treatment of type 2 diabetes

Polster, Michael R.; Zanutto, Elaine; McDonald, Susan; Conner, Christopher S.; Hammer, Mette

doi:10.3111/13696998.2010.529377

Cited by 57 publications

(81 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All studies were cross-sectional, and sample sizes ranged from 129 to 1,355 participants. Half of the studies were performed in the U.S. (9–11,15,16), and the remaining studies included participants from Sweden (12,13), Denmark (7), and the U.K. (8,11,14). Industry/pharmaceutical companies funded the majority of the studies (7,8,11–16) (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…Methods to assess patient preferences for noninsulin diabetes medications included the following: discrete choice experiments (7,11–13), time tradeoff methods (9,10), conjoint analysis exercises combined with time tradeoff (16), survey questions with Likert-type ratings scales (15), and standard gamble (8,14) (Tables 1 and 2). …”

Section: Resultsmentioning

confidence: 99%

“…These comparisons included specific diabetes medications, such as liraglutide, rosiglitazone, and exenatide (12,16), as well as broader categories of medication types (e.g., oral drugs vs. injections) (7,13,15). Several studies included hypothetical medication profiles of treatment attributes (e.g., intensive vs. conventional treatment) to assess patient preferences (8–12,14) (Table 2).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review

et al. 2014

View full text Add to dashboard Cite

OBJECTIVEAn evidence-based synthesis of patient preferences for management of hyperglycemia is needed. Our objective was to systematically review patient preferences for noninsulin diabetes medications in adults with type 2 diabetes.RESEARCH DESIGN AND METHODSWe searched the PubMed, Embase, CINAHL, and EconLit databases for articles published on or before 23 January 2013. We included English-language studies of adult patients with type 2 diabetes that assessed patient preferences for diabetes medication treatment. Titles, abstracts, and articles were reviewed by at least two independent reviewers. Study data and quality were abstracted with standard protocols.RESULTSOf 2,811 titles identified in our original search, 10 articles met inclusion criteria for the systematic review. Studies were conducted from 2007 to 2012 among diverse patient populations in the U.S., Sweden, Denmark, and the U.K. Methods used to assess patient preferences included discrete choice experiments (e.g., conjoint analysis), time tradeoff exercises, standard gamble, and patient surveys. Key attributes of diabetes medication associated with patient preferences included treatment benefits (e.g., glycemic control and weight loss/control), treatment burden (e.g., administration, frequency, and cost), and side effects (e.g., weight gain, gastrointestinal effects, and hypoglycemia).CONCLUSIONSVarious clinical and quality of life–related factors influence patient preferences for noninsulin diabetes medications. Treatment efficacy with regard to glycemic control and weight loss/control and the risk of treatment-related hypoglycemia and gastrointestinal effects are reported to be important drivers of patient treatment selections. Future work is needed to identify practical methods for incorporating patient preferences into treatment decision making and patient-centered care.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review

et al. 2014

View full text Add to dashboard Cite

show abstract

“…20,21,39 The current study builds on this previous research by quantifying patient preferences for some key injection-related attributes of weekly GLP-1 receptor agonists. In addition to providing further insight into patient preferences, the resulting utility scores may be useful in economic modeling of these treatments.…”

Section: Resultsmentioning

confidence: 99%

Patient Preferences In Italy: Health State Utilities Associated With Attributes Of Weekly Injection Devices For Treatment Of Type 2 Diabetes

et al. 2017

View full text Add to dashboard Cite

“…Patients utilizing GLP-1 RAs as part of their T2DM therapy have reported improved quality of life and satisfaction with treatment, particularly for the once daily and once weekly preparations [45,[47][48][49].…”

Section: Glp-1 Receptor Agonistsmentioning

confidence: 99%

Impact of Newer Medications for Type 2 Diabetes on Body Weight

Pedersen¹

2013

Curr Obes Rep

View full text Add to dashboard Cite

Most patients with type 2 diabetes (T2DM) struggle with excess body weight. Many management strategies for achievement of euglycemia in T2DM are associated with weight gain, which worsens insulin resistance over time, increases health risk associated with obesity, and is associated with poor compliance with treatment. This review will discuss a host of new medications for management of hyperglycemia that have emerged and are emerging which are weight neutral, or facilitate weight loss. Incretin therapies are reviewed, including DPP-4 inhibitors which are weight neutral, and GLP-1 receptor agonists which can facilitate weight loss. SGLT-2 inhibitors, anticipated to become available soon, facilitate modest weight loss. Pramlintide can improve glycemic control and facilitate weight loss in T2DM patients on concomitant insulin therapy. The bile acid sequestering agent colesevelam, more recently approved for management of T2DM, modestly improves glycemic control and is weight neutral. The advent of these newer therapies makes it increasingly possible to optimize concomitant management of type 2 diabetes and obesity.

show abstract

A comparison of preferences for two GLP-1 products – liraglutide and exenatide – for the treatment of type 2 diabetes

Abstract: Based on the four attributes presented, patients prefer liraglutide over exenatide. Preference is based on superior efficacy and less nausea more than less hypoglycemia and once-daily dosing.

Cited by 57 publications

References 24 publications

Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review

Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review

Patient Preferences In Italy: Health State Utilities Associated With Attributes Of Weekly Injection Devices For Treatment Of Type 2 Diabetes

Impact of Newer Medications for Type 2 Diabetes on Body Weight

Contact Info

Product

Resources

About